(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.03%) $0.926
(-0.08%) $10.83
(-0.15%) $0.791
(-0.21%) $92.38
@ $28.94
Issued: 14 Feb 2024 @ 13:53
Return: -6.91%
Previous signal: Feb 13 - 15:50
Previous signal:
Return: 0.59 %
Live Chart Being Loaded With Signals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases...
Stats | |
---|---|
Today's Volume | 482 710 |
Average Volume | 734 254 |
Market Cap | 2.44B |
EPS | $0 ( 2024-02-26 ) |
Next earnings date | ( $-0.690 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.23 |
ATR14 | $0.0350 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Makker Gotham | Sell | 274 000 | Common Stock |
2023-02-14 | Militello John | Buy | 11 067 | Common Stock |
2024-03-21 | Militello John | Sell | 2 490 | Common Stock |
2022-08-12 | Militello John | Buy | 14 310 | Common Stock |
2022-04-18 | Militello John | Buy | 7 932 | Common Stock |
INSIDER POWER |
---|
50.08 |
Last 99 transactions |
Buy: 5 058 785 | Sell: 1 586 966 |
Volume Correlation
Rocket Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Rocket Pharmaceuticals Correlation - Currency/Commodity
Rocket Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-7.10M (0.00 %) |
EPS: | $-2.92 |
Q4 | 2023 |
Revenue: | $10.31M |
Gross Profit: | $5.16M (50.00 %) |
EPS: | $-0.000700 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-1.76M (0.00 %) |
EPS: | $-0.750 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-1.72M (0.00 %) |
EPS: | $-0.820 |
Financial Reports:
No articles found.
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators